News
Pembrolizumab plus chemotherapy demonstrated the greatest survival benefit compared with other immune checkpoint inhibitors (ICIs) across all PD-L1 expression levels in the first-line treatment of advanced non-small cell lung cancer (NSCLC), according to a meta-analysis presented at the IASLC 2019 World Conference on Lung Cancer. Randomized clinical trials evaluating first-line ICI alone or in combination…
News
Treatment with selpercatinib (LOXO-292) was associated with high objective response rate (ORR) in heavily pretreated patients with RET fusion-positive non-small cell lung cancer (NSCLC), according to research presented at the IASLC 2019 World Conference on Lung Cancer. Researchers from Memorial Sloan Kettering Cancer Center presented data from the LIBRETTO-001 (LOXO-292 Investigated to Block RETaltered Tumors)…
News
Durvalumab added to standard-of-care (SoC) chemotherapy demonstrated significantly improved overall survival (OS) in treatment-naive patients with extensive-stage small cell lung cancer (SCLC), according to a phase 3 study presented at the IASLC 2019 World Conference on Lung Cancer. The CASPIAN trial was a randomized, open-label, multicenter, global, phase 3 study evaluating durvalumab in combination with…
News
Obesity and age do not appear to influence the survival of patients with non-small cell lung cancer (NSCLC) treated with programmed death receptor-1 (PD-1)/programmed cell death ligand 1 (PD-L1) immune checkpoint inhibitors (ICI), according to an analysis presented at the IASLC 2019 World Conference on Lung Cancer. To better understand how age and body mass…
Drugs in the Pipeline
The FDA has accepted for review the New Drug Application (NDA) for Eagle's ready-to-dilute (RTD) Pemetrexed Injection 25mg/mL for the treatment of locally advanced or metastatic nonsquamous non-small cell lung cancer and mesothelioma (in combination with cisplatin).
Drugs in the Pipeline
Ariad Pharmaceuticals announced the initiation of the first part of a rolling New Drug Application (NDA) submission to the Food and Drug Administration (FDA) for its investigational agent, brigatinib, for the treatment of patients with anaplastic lymphoma kinase positive (ALK+) non-small cell lung cancer (NSCLC) who are resistant to crizotinib.
Drugs in the Pipeline
AstraZeneca announced that the FDA has granted Orphan Drug designation to selumetinib for the adjuvant treatment of patients with stage III or IV differentiated thyroid cancer (DTC).
Drugs in the Pipeline
Genentech announced that the Food and Drug Administration (FDA) has accepted and granted Priority Review to the Biologics License Application (BLA) for atezolizumab (anti-PDL1; MPDL3280A
News
Merck announced that the Food and Drug Administration (FDA) has accepted for review a new supplemental Biologics License Application (sBLA) for Keytruda (pembrolizumab) to include data from the Phase 2/3 study KEYNOTE-010 for the treatment of metastatic non-small cell lung cancer (NSCLC).
Drugs in the Pipeline
Bristol-Myers Squibb announced that the CheckMate -141 trial evaluating Opdivo (nivolumab) vs. investigator's choice in patients with recurrent or metastatic platinum-refractory squamous cell carcinoma of the head and neck (SCCHN) was stopped early due to the study meeting its primary endpoint.
